Manish Parikh, MD
Internal Medicine · Brooklyn, NYNPI 1891882965
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (42.0%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 53 manufacturers reported payments, led by Boston Scientific at 39.9% of the total. Reporting peaked in 2019 at $92,857 and has fallen 70.3% since, to $27,584 in 2025. Among internal medicine clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 722 payments — averaging $326.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$94K
- Medtronic$66K
- Abbott$10K
- Siemens Medical Solutions USA, Inc.$10K
- Cardiovascular Systems Inc.$9K
- Corindus Inc.$7K
- plus $40K from 47 others
Across 45 payments — averaging $14,545 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Cardiovascular Systems Inc.$543K
- Siemens Medical Solutions USA, Inc.$42K
- Corindus Inc.$35K
- Boston Scientific$35K
What the payments were for
- Consulting fees$64,65527%
- Speaking & faculty fees$99,16042%
- Travel & lodging$29,72113%
- Food & beverage$42,00518%
- Education$3060%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL VASCULAR ACCESS$48,062
- GENERAL - THERAPIES$24,756
- Resolute$20,172
- Onyx$10,495
- Xience V coronary stent system$8,831
- Coronary Orbital Atherectomy System$7,508
- SYMPLICITY G3$6,741
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$5,168
- LifeVest$5,000
- CorPath GRX$4,882
- Paradise Ultrasound Renal Denervation System$4,647
- AVVIGO Guidance System$3,032
- ENDOCROSS Device$1,600
- Torus Stent Graft System$1,600
- RESOLUTE ONYX$1,537
- PERIPHERAL VASCULAR$1,500
- Diamondback Coronary$1,410
- ONYX FRONTIER$1,390
- PK Papyrus$1,200
- Astron; Pulsar; AstronPulsar$1,200
How this compares
$235,848 in reported general payments places this provider in the 95th percentile of 9,771 internal medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 204 | $255,290 |
| EntrestoSacubitril/Valsartan | 189 | $238,076 |
| JardianceEmpagliflozin | 139 | $167,174 |
| Repatha SureclickEvolocumab | 112 | $89,360 |
| FarxigaDapagliflozin Propanediol | 74 | $79,451 |
| BrilintaTicagrelor | 67 | $63,382 |
| Praluent PenAlirocumab | 63 | $44,714 |
| JanuviaSitagliptin Phosphate | 17 | $26,657 |
| VascepaIcosapent Ethyl | 29 | $19,940 |
| XareltoRivaroxaban | 18 | $17,840 |
| OzempicSemaglutide | 11 | $10,985 |
| Rosuvastatin Calcium | 650 | $9,947 |
| Metoprolol Succinate | 389 | $5,330 |
| Ranolazine ErRanolazine | 59 | $4,982 |
| ClopidogrelClopidogrel Bisulfate | 400 | $4,441 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $390 | $255,290204 claims |
| NovartisEntresto | $602 | $238,076189 claims |
| Boehringer IngelheimJardiance | $493 | $167,174139 claims |
| AstraZenecaFarxiga, Brilinta, Symbicort | $616 | $145,592153 claims |
| Johnson & JohnsonXarelto | $81 | $17,84018 claims |
| Novo NordiskOzempic | $24 | $10,98511 claims |
| AbbVieSynthroid | $146 | $67011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in Brooklyn
- Bruce BergerBrooklyn$3.4M
- Jesi RamoneBrooklyn$627K
- Samuel UterBrooklyn$136K
- David DoveEast Hampton$12.3M
- Nicholas RobinsonBuffalo$2.9M
- Stephen SaletanNew York$2.6M
- Ziad AliNew York$2M
- Scott BeegleAlbany$1.9M
- Anthony MartinezBuffalo$1.6M
- Javier MoralesGreenvale$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.